The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.
 
Daniel J. George
Honoraria - Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Novartis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer
 
Jean-Francois Martini
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Michael D. Staehler
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis; Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
 
Yen-Hwa Chang
No Relationships to Disclose
 
Jan Breza
No Relationships to Disclose
 
Jean-Jacques Patard
No Relationships to Disclose
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
 
Ahmed Magheli
Honoraria - Astellas Pharma; Bayer; Janssen; Pfizer
 
Giacomo Carteni
No Relationships to Disclose
 
Frede Donskov
Research Funding - Novartis; Pfizer
 
Bernard Escudier
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EUSA Pharma; Exelixis; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Sherry Li
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Michelle Casey
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Olga Valota
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Brigitte Laguerre
Honoraria - Bristol-Myers Squibb; novartis; pfizer; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; novartis; pfizer; pfizer
 
Allan J. Pantuck
Consulting or Advisory Role - Pfizer
 
Hardev S. Pandha
No Relationships to Disclose
 
Anup Patel
No Relationships to Disclose
 
Mariajose Lechuga
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Alain Ravaud
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer